Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20615613 | 0.84 | FUCA1 (0.41) | MTNR1ACYP2D6MTNR1B | |
| SCHEMBL21973388 | 0.84 | FUCA1 (0.41) | MTNR1ACYP2D6MTNR1B | |
| SCHEMBL22546944 | 0.81 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL22005539 | 0.81 | MTNR1A (0.40) | MTNR1AMEN1KMT2AMTNR1B | |
| SCHEMBL23165447 | 0.80 | MTNR1A (0.32) | MTNR1ACYP2D6MTNR1B | |
| SCHEMBL20685675 | 0.80 | MTNR1A (0.32) | MTNR1ACYP2D6MTNR1B | |
| SCHEMBL22005538 | 0.80 | CYP2D6 (0.31) | CYP2D6 | |
| SCHEMBL23165445 | 0.80 | MTNR1A (0.32) | MTNR1ACYP2D6MTNR1B | |
| SCHEMBL20685659 | 0.80 | MTNR1A (0.32) | MTNR1ACYP2D6MTNR1B | |
| SCHEMBL4761527 | 0.73 | CYP2D6 (0.53) | MTNR1AMEN1KMT2ACYP2D6PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | MTNR1A 2380/4885MEN1 4183/4885KMT2A 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.